The Food and Drug Administration will give priority review to a first-of-its-kind maternal vaccine against respiratory syncytial virus via the breakthrough therapy program.
The Food and Drug Administration will give priority review to a first-of-its-kind maternal vaccine against respiratory syncytial virus via the breakthrough therapy program.